title: [Not Available].
abstract: Chemotherapy with docetaxel has remained a cornerstone of second-line treatment for more than 15 years, but it is associated with an unfavorable safety profile. Recently, the results of 2 randomized phase III trials assessing nivolumab in lung cancer, Check-Mate-017 and Check- Mate-057, have deeply changed our current clinical practice and open the debate for further improvements in the clinical care of lung cancer. This paper explores the recent findings about nivolumab in the second-line setting and discusses future directions for nivolumab and other immune Oncology drugs.
authors: UM Oncologie Thoracique, Clinique de pneumologie, PTV CHU Grenoble-Alpes, CS10217 38043 Grenoble cedex; Inserm U823, Institut Albert Bonniot, Rond-point de la chantourne 38700 La tronche. Electronic address: dmorot-sibilot@chu-grenoble.fr.
authors: Denis
authors: D
authors: Moro-Sibilot
authors: UM Oncologie Thoracique, Clinique de pneumologie, PTV CHU Grenoble-Alpes, CS10217 38043 Grenoble cedex.
authors: Léonie
authors: L
authors: Ferrer
authors: UM Oncologie Thoracique, Clinique de pneumologie, PTV CHU Grenoble-Alpes, CS10217 38043 Grenoble cedex.
authors: Matteo Giaj
authors: MG
authors: Levra
authors: UM Oncologie Thoracique, Clinique de pneumologie, PTV CHU Grenoble-Alpes, CS10217 38043 Grenoble cedex; Inserm U823, Institut Albert Bonniot, Rond-point de la chantourne 38700 La tronche.
authors: Anne Claire
authors: AC
authors: Toffart
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000077594:Nivolumab; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D000077594:Nivolumab
keywords: Cancers bronchiques; Chemotherapy; Chimiothérapie; Immunotherapy; Immunothérapie; Lung cancer; Targeted therapy; Thérapeutiques ciblées